Patents by Inventor Alejandro Santillan

Alejandro Santillan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TETRAHYDROISOQUINOLINE COMPOUNDS AS MODULATORS OF THE HISTAMINE H3 RECEPTOR
    Publication number: 20090099158
    Abstract: Certain substituted tetrahydroisoquinoline compounds are histamine H3 receptor modulators useful in the treatment of histamine H3 receptor-mediated diseases.
    Type: Application
    Filed: February 28, 2008
    Publication date: April 16, 2009
    Inventors: Cheryl A. Grice, Michael A. Letavic, Alejandro Santillan, JR., Kimberly L. Schwarz
  • SUBSTITUTED BENZAMIDE MODULATORS OF THE HISTAMINE H3 RECEPTOR
    Publication number: 20080045507
    Abstract: Certain substituted benzamide compounds are histamine H3 receptor modulators useful in the treatment of histamine H3 receptor-mediated diseases.
    Type: Application
    Filed: June 21, 2007
    Publication date: February 21, 2008
    Inventors: Brett D. Allison, Nicholas I. Carruthers, Michael A. Letavic, Alejandro Santillan, Chandravadan R. Shah
  • Aryl Piperidine Amides
    Publication number: 20080009521
    Abstract: The invention provides novel GlyT2 inhibiting compounds useful in modulating, treating, or preventing: anxiolytic disorders; a condition requiring treatment of injured mammalian nerve tissue; a condition amenable to treatment through administration of a neurotrophic factor; a neurological disorder; or obesity; an obesity-related disorder.
    Type: Application
    Filed: July 19, 2007
    Publication date: January 10, 2008
    Inventors: Charles Huang, Timothy Lovenberg, Alejandro Santillan, Liu Tang, Ronald Wolin
  • Aryl piperidine amides
    Patent number: 7276610
    Abstract: The invention provides novel GlyT2 inhibiting compounds useful in modulating, treating, or preventing: anxiolytic disorders; a condition requiring treatment of injured mammalian nerve tissue; a condition amenable to treatment through administration of a neurotrophic factor; a neurological disorder; or obesity; an obesity-related disorder.
    Type: Grant
    Filed: August 17, 2004
    Date of Patent: October 2, 2007
    Assignee: Janssen Pharaceutica, NV
    Inventors: Charles Q. Huang, Timothy W. Lovenberg, Alejandro Santillán, Jr., Liu Y. Tang, Ronald L. Wolin
  • GlyT2 modulators
    Patent number: 7202269
    Abstract: Certain ?-, ?-, and ?-amino acid derivatives are disclosed as selective GlyT2 inhibitors for the treatment of central nervous system (CNS) conditions such as muscle spasticity, tinnitus, epilepsy and neuropathic pain.
    Type: Grant
    Filed: October 28, 2004
    Date of Patent: April 10, 2007
    Assignee: Janssen Pharmaceutica N.V.
    Inventors: Tristin K. Barclay, Alejandro Santillán, Jr., Liu Y. Tang, Hariharan Venkatesan, Ronald L. Wolin
  • Bicyclic pyrazole compounds as antibacterial agents
    Publication number: 20060223810
    Abstract: Antibacterial compounds, compositions containing them, and methods of use for the inhibition of bacterial activity and the treatment, prevention or inhibition of bacterial infection.
    Type: Application
    Filed: March 30, 2006
    Publication date: October 5, 2006
    Inventors: Brett Allison, Laurent Gomez, Cheryl Grice, Michael Hack, Brian Morrow, S. Motley, Alejandro Santillan, Karen Shaw, Kimberly Schwarz, Liu Tang, Hariharan Venkatesan, John Wiener
  • GlyT2 modulators
    Publication number: 20050119245
    Abstract: Certain ?-, ?-, and ?-amino acid derivatives are disclosed as selective GlyT2 inhibitors for the treatment of central nervous system (CNS) conditions such as muscle spasticity, tinnitus, epilepsy and neuropathic pain.
    Type: Application
    Filed: October 28, 2004
    Publication date: June 2, 2005
    Inventors: Tristin Barclay, Alejandro Santillan, Liu Tang, Hariharan Venkatesan, Ronald Wolin
  • Aryl piperidine amides
    Publication number: 20050049239
    Abstract: The invention provides novel GlyT2 inhibiting compounds useful in modulating, treating, or preventing: anxiolytic disorders; a condition requiring treatment of injured mammalian nerve tissue; a condition amenable to treatment through administration of a neurotrophic factor; a neurological disorder; or obesity; an obesity-related disorder.
    Type: Application
    Filed: August 17, 2004
    Publication date: March 3, 2005
    Inventors: Charles Huang, Timothy Lovenberg, Alejandro Santillan, Liu Tang, Ronald Wolin